Last reviewed · How we verify
Placebo Methotrexate
Placebo Methotrexate is a Folate antagonist / Antimetabolite Small molecule drug developed by AbbVie. It is currently FDA-approved for Rheumatoid arthritis, Psoriasis, Psoriatic arthritis. Also known as: Intra-lesional, Sub-study.
Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation.
Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation. Used for Rheumatoid arthritis, Psoriasis, Psoriatic arthritis.
At a glance
| Generic name | Placebo Methotrexate |
|---|---|
| Also known as | Intra-lesional, Sub-study |
| Sponsor | AbbVie |
| Drug class | Folate antagonist / Antimetabolite |
| Target | Dihydrofolate reductase (DHFR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / Oncology |
| Phase | FDA-approved |
Mechanism of action
Methotrexate is a folate antagonist that inhibits the enzyme dihydrofolate reductase, which is essential for converting dihydrofolate to tetrahydrofolate in the one-carbon transfer pathway. This disruption reduces the synthesis of purines and pyrimidines, leading to decreased DNA and RNA synthesis. At lower doses used in rheumatologic conditions, it also has immunosuppressive and anti-inflammatory effects through adenosine release and inhibition of T-cell activation.
Approved indications
- Rheumatoid arthritis
- Psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
- Various malignancies (acute leukemias, lymphomas, breast cancer)
Common side effects
- Bone marrow suppression (anemia, leukopenia, thrombocytopenia)
- Hepatotoxicity
- Nephrotoxicity
- Mucositis / stomatitis
- Nausea and vomiting
- Alopecia
- Infection (due to immunosuppression)
Key clinical trials
- Local Methotrexate Injections for the Treatment of Nail Psoriasis (PHASE4)
- A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) (PHASE2)
- A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) (PHASE2)
- Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis (PHASE2)
- A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY) (PHASE2)
- A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis (PHASE1)
- Methotrexate and Metformin in Rheumatoid Arthritis Patients (PHASE2)
- CD40L Antagonism in Rheumatoid Arthritis (RA) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Methotrexate CI brief — competitive landscape report
- Placebo Methotrexate updates RSS · CI watch RSS
- AbbVie portfolio CI
Frequently asked questions about Placebo Methotrexate
What is Placebo Methotrexate?
How does Placebo Methotrexate work?
What is Placebo Methotrexate used for?
Who makes Placebo Methotrexate?
Is Placebo Methotrexate also known as anything else?
What drug class is Placebo Methotrexate in?
What development phase is Placebo Methotrexate in?
What are the side effects of Placebo Methotrexate?
What does Placebo Methotrexate target?
Related
- Drug class: All Folate antagonist / Antimetabolite drugs
- Target: All drugs targeting Dihydrofolate reductase (DHFR)
- Manufacturer: AbbVie — full pipeline
- Therapeutic area: All drugs in Immunology / Rheumatology / Oncology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Psoriasis
- Indication: Drugs for Psoriatic arthritis
- Also known as: Intra-lesional, Sub-study
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing